- Home
- WMB vs GSK Comparison
WMB vs GSK Comparison
Compare WMB & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WMB
- GSK
- Stock Information
- Founded
- WMB 1908
- GSK 1715
- Country
- WMB United States
- GSK United Kingdom
- Employees
- WMB N/A
- GSK N/A
- Industry
- WMB Natural Gas Distribution
- GSK Biotechnology: Pharmaceutical Preparations
- Sector
- WMB Utilities
- GSK Health Care
- Exchange
- WMB Nasdaq
- GSK Nasdaq
- Market Cap
- WMB 71.1B
- GSK 78.9B
- IPO Year
- WMB N/A
- GSK N/A
- Fundamental
- Price
- WMB $60.48
- GSK $41.01
- Analyst Decision
- WMB Buy
- GSK Hold
- Analyst Count
- WMB 17
- GSK 4
- Target Price
- WMB $58.27
- GSK $47.00
- AVG Volume (30 Days)
- WMB 7.2M
- GSK 5.1M
- Earning Date
- WMB 05-05-2025
- GSK 04-30-2025
- Dividend Yield
- WMB 3.31%
- GSK 3.91%
- EPS Growth
- WMB N/A
- GSK N/A
- EPS
- WMB 1.86
- GSK 0.98
- Revenue
- WMB $11,083,000,000.00
- GSK $40,735,668,430.00
- Revenue This Year
- WMB $12.06
- GSK $6.70
- Revenue Next Year
- WMB $10.46
- GSK $5.42
- P/E Ratio
- WMB $32.53
- GSK $20.21
- Revenue Growth
- WMB 9.13
- GSK 2.57
- 52 Week Low
- WMB $40.11
- GSK $31.72
- 52 Week High
- WMB $61.67
- GSK $45.01
- Technical
- Relative Strength Index (RSI)
- WMB 59.44
- GSK 66.32
- Support Level
- WMB $59.58
- GSK $39.05
- Resistance Level
- WMB $60.87
- GSK $39.65
- Average True Range (ATR)
- WMB 1.06
- GSK 0.60
- MACD
- WMB 0.23
- GSK 0.27
- Stochastic Oscillator
- WMB 91.24
- GSK 96.94
About WMB Williams Companies Inc. (The)
Williams Companies is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.